Expres2ion Biotechnologies: Completes GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate
Today Expres2ion Biotechnologies announced an important milestone on the ES2B-C001 (HER2-VLP) breast cancer vaccine candidate.
CEO Bent U. Frandsen commented "The completion of the GLP safety study for our ES2B-C001 (HER2-VLP) breast cancer vaccine candidate is a testament to our team's dedication and hard work. This is a significant step forward in our mission to bring a potentially life-saving treatment to patients. We are now focusing our efforts on GMP production and designing the clinical trial, with the goal of initiating clinical trials within the next year. We look forward to driving this project further and making a meaningful impact in the fight against breast cancer."
Read the full story here:Expres2ion Biotechnologies
Disclaimer: HC Andersen Capital receives payment from Expres2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 20:50 PM 16-04-2024.
ExpreS2ion Biotech Holding
ExpreS2ion Biotech Holding är ett forsknings- och utvecklingsbaserat bolag som har en patenterad plattform inom bioteknisk proteinproduktion. Bolaget har sin egen utvecklingspipeline av vaccinkandidater inom COVID-19, bröstcancer, influensa och malaria. Dessutom har bolaget intäkter från försäljning av tillverkningstjänster och plattformslicenser. Bolaget startade 2010 och har sin verksamhet i DTU Forskerpark i Hørsholm.
Read more on company page